Compare REVB & JCSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | JCSE |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.8M |
| IPO Year | N/A | 2022 |
| Metric | REVB | JCSE |
|---|---|---|
| Price | $1.13 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 64.4K | 33.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 9.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.77 |
| 52 Week High | $3.73 | $2.50 |
| Indicator | REVB | JCSE |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 44.75 |
| Support Level | $0.73 | $1.00 |
| Resistance Level | $1.20 | $1.10 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.27 | 16.67 |
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.